Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir
Ligand Pharmaceuticals' (NASDAQ: LGND) big slide in March was only short-lived. Its shares have rebounded nicely over the last several months and came into this week up 12% year to date. The biotech announced its second-quarter results before the market opened
LGND earnings call for the period ending June 30, 2020.
Motley Fool · 3天前
Ligand Pharmaceuticals shares are trading higher after the company raised its FY20 EPS and sales guidance above analyst estimates.
Benzinga · 3天前
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates
Ligand (LGND) delivered earnings and revenue surprises of 53.85% and 46.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3天前
Ligand Pharmaceuticals Raises FY2020 Adj EPS Guidance from $3.65 to $4.10 vs $3.71 Est; Raises FY2020 Sales Guidance from $140.00M to $165.00M vs $142.45M Est
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2020 Adj EPS guidance from $3.65 to $4.10 vs $3.71 analyst estimate. Raises FY2020 sales outlook from $140.00 million to $165.00 million vs $142.45 million estimate.
Benzinga · 4天前
Ligand Reports Second Quarter 2020 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginn